Journal ArticleDOI
The endocannabinoid system and psychiatric disorders.
TLDR
SR141716A and cannabidiol show the most constant antipsychotic properties in dopamine- and glutamate-based models of schizophrenia, with profiles similar to an atypical antipsychotics drug.About:
This article is published in Experimental Neurology.The article was published on 2010-07-01. It has received 134 citations till now. The article focuses on the topics: Psychosis & Endocannabinoid system.read more
Citations
More filters
Journal ArticleDOI
The Endocannabinoid System and the Brain
TL;DR: Research on the actions of the endocannabinoid system on anxiety, depression, neurogenesis, reward, cognition, learning, and memory, and the effects are at times biphasic--lower doses causing effects opposite to those seen at high doses.
Antidepressant-Like Activity and Modulation of Brain Monoaminergic Transmission by Blockade of Anandamide Hydrolysis
Gabriella Gobbi,Francis Rodriguez Bambico,Regina A. Mangieri,Marco Bortolato,Patrizia Campolongo,Tommaso Cassano,Maria Grazia Morgese,Guy Debonnel,Andrea Duranti,A. Tontini,Giorgio Tarzia,Marco Mor,Viviana Trezza,Steven R. Goldberg,Vincenzo Cuomo,Daniele Piomelli +15 more
TL;DR: Gobi et al. as discussed by the authors showed that URB597, a selective inhibitor of the enzyme fatty acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test.
Journal ArticleDOI
Cannabis and adolescent brain development.
TL;DR: A review of studies examining the acute and chronic effects of cannabis use on the brain, with a particular focus on the impact of commencing use during adolescence, identifies synaptic pruning and white matter development as two processes that may be adversely impacted by cannabis exposure during adolescence.
Journal ArticleDOI
Phytocannabinoids as novel therapeutic agents in CNS disorders
TL;DR: In this article, a review of non-Δ(9)-THC pCB effects in preclinical models of CNS disease and, where available, clinical trial data that support therapeutic effects is presented.
Journal ArticleDOI
Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana
TL;DR: This article explores each of these controversies, with the intent of educating physicians to decide for themselves whether marijuana is panacea, scourge, or both.
References
More filters
Journal ArticleDOI
A neurotrophic model for stress-related mood disorders.
TL;DR: Analysis of preclinical cellular and behavioral models of depression and antidepressant actions, as well as clinical neuroimaging and postmortem studies, are consistent with the hypothesis that decreased expression of BDNF and possibly other growth factors contributes to depression and that upregulation ofBDNF plays a role in the actions of antidepressant treatment.
Journal ArticleDOI
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review
Theresa Hm Moore,Stanley Zammit,Stanley Zammit,Anne Lingford-Hughes,Thomas R. E. Barnes,Peter B. Jones,Margaret Burke,Glyn Lewis +7 more
TL;DR: There is now sufficient evidence to warn young people that using cannabis could increase their risk of developing a psychotic illness later in life, although evidence for affective outcomes is less strong.
Journal ArticleDOI
The molecular logic of endocannabinoid signalling
TL;DR: The endocannabinoids are a family of lipid messengers that engage the cell surface receptors that are targeted by Δ9-tetrahydrocannabinol, the active principle in marijuana (Cannabis).
Journal ArticleDOI
The endogenous cannabinoid system controls extinction of aversive memories
Giovanni Marsicano,Carsten T. Wotjak,Shahnaz Christina Azad,Shahnaz Christina Azad,Tiziana Bisogno,Gerhard Rammes,Maria Grazia Cascio,Heike Hermann,Jianrong Tang,Clementine Hofmann,Walter Zieglgänsberger,Vincenzo Di Marzo,Beat Lutz +12 more
TL;DR: Treatment of wild-type mice with the CB1 antagonist SR141716A mimicked the phenotype of CB1-deficient mice, revealing that CB1 is required at the moment of memory extinction, and proposes that endocannabinoids facilitate extinction of aversive memories through their selective inhibitory effects on local inhibitory networks in the amygdala.
Journal ArticleDOI
New approaches to antidepressant drug discovery: beyond monoamines
Olivier Berton,Eric J. Nestler +1 more
TL;DR: A recent review summarizes the obstacles that have hindered the development of non-monoamine-based antidepressants, and provides a progress report on some of the most promising current strategies as discussed by the authors.